Increased oxidative stress in patients with depression and its relationship to treatment

Psychiatry Research

Volumn 206, Issue 2-3, 2013, Pages 213-216

  Chung, Cecilia P ^a   Schmidt, Dennis ^a   Stein, Charles Michael ^a,b   Morrow, Jason D ^a,b   Salomon, Ronald M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Bupropion; Depression; F2 isoprostanes; Oxidative stress; Sertraline

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; SERTRALINE;

ADULT; ARTICLE; CASE CONTROL STUDY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; OXIDATIVE STRESS; SEVERITY OF ILLNESS INDEX; URINE;

ADULT; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; BUPROPION; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER, MAJOR; F2-ISOPROSTANES; FEMALE; HUMANS; MALE; OXIDATIVE STRESS; SERTRALINE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

MLCS; MLOWN;

EID: 85027924258     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.10.018     Document Type: Article

References (31)

1. Avalos, I., Chung, C.P., Oeser, A., Milne, G.L., Morrow, J.D., Gebretsadik, T., Shintani, A., Yu, C., Stein, C.M., Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. Lupus 16 (2007), 195–200.
2. Bautista-Ferrufino, M.R., Cordero, M.D., Sanchez-Alcazar, J.A., Illanes, M., Fernandez-Rodriguez, A., Navas, P., de, M.R., Amitriptyline induces coenzyme Q deficiency and oxidative damage in mouse lung and liver. Toxicology Letters 204 (2011), 32–37.
3. Belmaker, R.H., Agam, G., Major depressive disorder. New England Journal of Medicine 358 (2008), 55–68.
4. Bilici, M., Efe, H., Koroglu, M.A., Uydu, H.A., Bekaroglu, M., Deger, O., Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. Journal of Affective Disorders 64 (2001), 43–51.
5. Cracowski, J.L., Durand, T., Bessard, G., Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends in Pharmacological Science 23 (2002), 360–366.
6. Cumurcu, B.E., Ozyurt, H., Etikan, I., Demir, S., Karlidag, R., Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry and Clinical Neurosciences 63 (2009), 639–645.
7. First, M.B., Spitzer, R.L., Williams, J.B.W., Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). 1996, American Psychiatric Press, Inc., Washington, DC.
8. Garland, S.N., Carlson, L.E., Cook, S., Lansdell, L., Speca, M., A non-randomized comparison of mindfulness-based stress reduction and healing arts programs for facilitating post-traumatic growth and spirituality in cancer outpatients. Supportive Care Cancer 15 (2007), 949–961.
9. Halliwell, B., Lee, C.Y., Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxidants and Redox Signaling 13 (2010), 145–156.
10. Hamilton, M., A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23 (1960), 56–62.
11. Inkielewicz-Stepniak, I., Impact of fluoxetine on liver damage in rats. Pharmacological Reports 63 (2011), 441–447.
12. Kirkova, M., Tzvetanova, E., Vircheva, S., Zamfirova, R., Grygier, B., Kubera, M., Antioxidant activity of fluoxetine: studies in mice melanoma model. Cell Biochemistry and Function 28 (2010), 497–502.
13. Kotan, V.O., Sarandol, E., Kirhan, E., Ozkaya, G., Kirli, S., Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Progress in Neuropsychopharmacology and Biological Psychiatry 35 (2011), 1284–1290.
14. Kumar, A., Garg, R., Gaur, V., Kumar, P., Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice. Brain Research 1311 (2010), 73–80.
15. Lawson, J.A., Rokach, J., Fitzgerald, G.A., Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. Journal of Biological Chemistry 274 (1999), 24441–24444.
16. Mazure, C., Nelson, J.C., Price, L.H., Reliability and validity of the symptoms of major depressive illness. Archives of General Psychiatry 43 (1986), 451–456.
17. Milne, G.L., Sanchez, S.C., Musiek, E.S., Morrow, J.D., Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nature Protocols 2 (2007), 221–226.
18. Morriss, R., Leese, M., Chatwin, J., Baldwin, D., Inter-rater reliability of the Hamilton Depression Rating Scale as a diagnostic and outcome measure of depression in primary care. Journal of Affective Disorders 111 (2008), 204–213.
19. Morrow, J.D., Chen, Y., Brame, C.J., Yang, J., Sanchez, S.C., Xu, J., Zackert, W.E., Awad, J.A., Roberts, L.J., The isoprostanes: unique prostaglandin-like products of free-radical-initiated lipid peroxidation. Drug Metabolism Reviews 31 (1999), 117–139.
20. Morrow, J.D., Roberts, L.J., Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods in Enzymology 233 (1994), 163–174.
21. Ng, F., Berk, M., Dean, O., Bush, A.I., Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. International Journal of Neuropsychopharmacology 11 (2008), 851–876.
22. Nourooz-Zadeh, J., Key issues in F2-isoprostane analysis. Biochemical Society Transactions 36 (2008), 1060–1065.
23. Ozcan, M.E., Gulec, M., Ozerol, E., Polat, R., Akyol, O., Antioxidant enzyme activities and oxidative stress in affective disorders. International Clinical Psychopharmacology 19 (2004), 89–95.
24. Roberts, L.J., Morrow, J.D., Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radical Biology and Medicine 28 (2000), 505–513.
25. Sarandol, A., Sarandol, E., Eker, S.S., Erdinc, S., Vatansever, E., Kirli, S., Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative–antioxidative systems. Human Psychopharmacology 22 (2007), 67–73.
26. Selley, M.L., Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. Journal of Affective Disorders 80 (2004), 249–256.
27. Sies, H., Jones, D.P., Oxidative Stress. Encyclopedia of Stress. 2007, Elsevier San Diego pp. 45–48.
28. Slamon, N.D., Pentreath, V.W., Antioxidant defense against antidepressants in C6 and 1321N1 cells. Chemico Biological Interactions 127 (2000), 181–199.
29. Teyssier, J.R., Ragot, S., Chauvet-Gelinier, J.C., Trojak, B., Bonin, B., Expression of oxidative stress–response genes is not activated in the prefrontal cortex of patients with depressive disorder. Psychiatry Research 186 (2011), 244–247.
30. Yager, S., Forlenza, M.J., Miller, G.E., Depression and oxidative damage to lipids. Psychoneuroendocrinology 35 (2010), 1356–1362.
31. Yanik, M., Erel, O., Kati, M., The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatrica 16 (2004), 200–203.